NLRP3 and diffuse large B-cell lymphoma: As for the first mechanism, several polymorphisms of NLRP3 inflammasome-related molecules were shown to confer increased susceptibility to DLBCL development and were also correlated with patients’ survival, prognosis, and treatment response [101,102].